Newsroom
Sight Sciences Announces Long-Term Safety and Effectiveness Data of Standalone Use of the OMNI® Surgical System in Patients with Open Angle Glaucoma
Three-year, standalone (not combined with cataract surgery) data shows the non-implantable minimally invasive glaucoma surgery effectively reduces intraocular pressure and reduces need for IOP-lowering medications in open-angle glaucoma patients
Sight Sciences Reports Second Quarter 2022 Financial Results
Sight Sciences Reports Second Quarter 2022 Financial Results August 11, 2022 PDF Version MENLO PARK, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today reported financial results for the second quarter ended […]
Sight Sciences to Report Second Quarter 2022 Financial Results on August 11, 2022
MENLO PARK, Calif., July 28, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced it will report financial results for the second quarter ended June 30, 2022, after the market close on Thursday, August 11, 2022. […]
Sight Sciences Announces the Appointment of Tamara Fountain, M.D. to its Board of Directors
MENLO PARK, Calif., July 19, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced the appointment of Tamara Fountain, M.D. to its Board of Directors, effective July 15, 2022. As part of her duties, Dr. Fountain […]
Sight Sciences’ OMNI® Surgical System Reduces IOP, Daily Fluctuations in IOP and Medication Use, as Shown in Newly Published 12-Month Clinical Data
Suppression of diurnal, or daily, fluctuations in IOP, is a significant and independent risk factor for the progression of glaucoma. These 12-month outcomes were also confirmed by results from a subset of the study, assessing the Hispanic patient population
Sight Sciences Reports First Quarter 2022 Financial Results
Sight Sciences Reports First Quarter 2022 Financial Results May 10, 2022 PDF Version MENLO PARK, Calif., May 10, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today reported financial results for the quarter ended March […]
Sight Sciences Reports Fourth Quarter and Full Year 2021 Financial Results
MENLO PARK, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today reported financial results for the quarter and year ended December 31, 2021.
Sight Sciences Announces First Patient Treated in TRIDENT European Trial to Evaluate the OMNI® Surgical System in Pseudophakic Eyes with Open-Angle Glaucoma
Novel trial design will compare safety and effectiveness outcomes for the OMNI Surgical System and the iStent inject® in lowering intraocular pressure (IOP) as a standalone treatment option without concomitant cataract surgery.